For 2023, ImmunoGen expects: Revenues, excluding product revenue from ELAHERE, between $30 million and $35 million; and operating expenses between $310 million and $320 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMGN: